Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI atai Life Sciences	$2.20 -2.2%	$1.92	$1.03 ▼ $2.64	$440.75M	1.47	1.74 million shs	963,664 shs
AURA Aura Biosciences	$6.28 -0.2%	$5.95	$4.35 ▼ $12.38	$315.70M	0.43	209,378 shs	1.31 million shs
GLUE Monte Rosa Therapeutics	$4.60 -1.3%	$4.51	$3.50 ▼ $12.40	$282.95M	1.41	1.08 million shs	942,428 shs
MNOV MediciNova	$1.33 +2.3%	$1.41	$1.12 ▼ $2.55	$65.24M	0.42	36,131 shs	15,976 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI atai Life Sciences	0.00%	-11.29%	-3.08%	+61.76%	+65.41%
AURA Aura Biosciences	0.00%	+3.97%	+7.53%	+7.17%	-16.93%
GLUE Monte Rosa Therapeutics	0.00%	-0.65%	+11.11%	-0.86%	+22.99%
MNOV MediciNova	0.00%	+3.10%	-5.67%	-8.90%	-7.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATAI atai Life Sciences	2.9069 of 5 stars	3.7	3.0	2.5	1.7	0.6
AURA Aura Biosciences	2.6025 of 5 stars	3.6	1.0	3.2	3.3	0.0
GLUE Monte Rosa Therapeutics	1.8006 of 5 stars	3.3	0.0	2.7	1.7	0.6
MNOV MediciNova	1.9697 of 5 stars	3.8	2.0	2.2	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI atai Life Sciences	3.33	Buy	$8.67	293.94% Upside
AURA Aura Biosciences	3.25	Buy	$22.00	250.32% Upside
GLUE Monte Rosa Therapeutics	2.67	Moderate Buy	$15.33	233.33% Upside
MNOV MediciNova	3.50	Strong Buy	$7.00	426.32% Upside

Current Analyst Ratings Breakdown

Latest MNOV, AURA, ATAI, and GLUE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	MNOV MediciNova	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy ➝ Strong-Buy	$6.00 ➝ $5.00
5/28/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$22.00
5/23/2025	AURA Aura Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$19.00
5/20/2025	ATAI atai Life Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$5.00
5/20/2025	ATAI atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/13/2025	ATAI atai Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/9/2025	MNOV MediciNova	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI atai Life Sciences	$310K	1,421.77	N/A	N/A	$0.69 per share	3.19
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$3.04 per share	N/A
GLUE Monte Rosa Therapeutics	$75.62M	3.74	N/A	N/A	$3.63 per share	1.27
MNOV MediciNova	$1M	65.24	N/A	N/A	$1.07 per share	1.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI atai Life Sciences	-$149.27M	-$0.91	N/A	N/A	N/A	N/A	-102.10%	-77.55%	8/12/2025 (Estimated)
AURA Aura Biosciences	-$86.92M	-$1.90	N/A	N/A	N/A	N/A	-58.63%	-49.74%	8/14/2025 (Estimated)
GLUE Monte Rosa Therapeutics	-$72.70M	$0.08	57.51	N/A	N/A	3.86%	2.65%	1.65%	8/14/2025 (Estimated)
MNOV MediciNova	-$11.04M	-$0.23	N/A	N/A	N/A	N/A	-20.77%	-19.68%	8/6/2025 (Estimated)

Latest MNOV, AURA, ATAI, and GLUE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	AURA Aura Biosciences	-$0.47	-$0.55	-$0.08	-$0.55	N/A	N/A
5/14/2025	Q1 2025	ATAI atai Life Sciences	-$0.19	-$0.15	+$0.04	-$0.15	N/A	$1.56 million
5/13/2025	Q1 2025	MNOV MediciNova	-$0.14	-$0.06	+$0.08	-$0.06	N/A	N/A
5/8/2025	Q1 2025	GLUE Monte Rosa Therapeutics	-$0.24	$0.57	+$0.81	$0.57	$13.57 million	$84.93 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI atai Life Sciences	N/A	N/A	N/A	N/A	N/A
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
MNOV MediciNova	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI atai Life Sciences	0.08	4.07	4.07
AURA Aura Biosciences	N/A	11.06	11.06
GLUE Monte Rosa Therapeutics	N/A	5.61	5.61
MNOV MediciNova	N/A	17.66	17.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI atai Life Sciences	28.41%
AURA Aura Biosciences	96.75%
GLUE Monte Rosa Therapeutics	79.96%
MNOV MediciNova	9.90%

Insider Ownership

Company	Insider Ownership
ATAI atai Life Sciences	26.80%
AURA Aura Biosciences	5.40%
GLUE Monte Rosa Therapeutics	6.50%
MNOV MediciNova	13.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI atai Life Sciences	80	200.34 million	146.65 million	Optionable
AURA Aura Biosciences	50	50.27 million	47.55 million	Not Optionable
GLUE Monte Rosa Therapeutics	90	61.51 million	57.51 million	Optionable
MNOV MediciNova	10	49.05 million	42.38 million	Optionable

MNOV, AURA, ATAI, and GLUE Headlines

Recent News About These Companies

MediciNova, Inc. (MNOV) stock price, news, quote & history - Yahoo Finance

June 26, 2025 | sg.finance.yahoo.com

FY2025 Earnings Estimate for MediciNova Issued By B. Riley

June 18, 2025 | marketbeat.com

MediciNova price target lowered to $5 from $6 at B. Riley

June 17, 2025 | finance.yahoo.com

B. Riley Comments on MediciNova's Q2 Earnings (NASDAQ:MNOV)

June 17, 2025 | marketbeat.com

B. Riley Lowers MediciNova (NASDAQ:MNOV) Price Target to $5.00

June 16, 2025 | marketbeat.com

MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025

April 14, 2025 | globenewswire.com

MediciNova says first patient enrolled in EAP trial to evaluate MN-166

April 9, 2025 | markets.businessinsider.com

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

April 8, 2025 | globenewswire.com

MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial…

December 9, 2024 | msn.com

MediciNova, Inc. Announces Interim Analysis Results from COMBAT-ALS Trial of MN-166 at International Symposium on ALS/MND

December 5, 2024 | quiverquant.comQ

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

December 5, 2024 | globenewswire.com

MediciNova Inc.

December 5, 2024 | wsj.com

D. Boral Capital Initiates Coverage of MediciNova (MNOV) with Buy Recommendation

December 3, 2024 | msn.com

MediciNova, Inc.: MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

November 20, 2024 | finanznachrichten.de

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

November 20, 2024 | finance.yahoo.com

MediciNova provides update in letter to stockholders

November 20, 2024 | markets.businessinsider.com

MediciNova, Inc. Provides Corporate Update and Highlights Ongoing Clinical Trials for MN166 and Other Programs

November 19, 2024 | quiverquant.comQ

MediciNova, Inc. Receives Notice of Allowance for Patent on MN-001 Method to Decrease Triglyceride Synthesis in the Liver

November 15, 2024 | quiverquant.comQ

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New ...

November 14, 2024 | bakersfield.comB

MediciNova granted Notice of Allowance for MN-001 patent by USPTO

November 14, 2024 | markets.businessinsider.com

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

November 14, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback
By Thomas Hughes | June 23, 2025
View Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback

MNOV, AURA, ATAI, and GLUE Company Descriptions

atai Life Sciences NASDAQ:ATAI

$2.20 -0.05 (-2.22%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.27 +0.07 (+3.36%)

As of 05:41 AM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Aura Biosciences NASDAQ:AURA

$6.28 -0.01 (-0.16%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$7.30 +1.02 (+16.24%)

As of 04:00 AM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Monte Rosa Therapeutics NASDAQ:GLUE

$4.60 -0.06 (-1.29%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.76 +0.16 (+3.50%)

As of 05:45 AM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

MediciNova NASDAQ:MNOV

$1.32 +0.02 (+1.92%)

As of 06/27/2025 04:00 PM Eastern

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time